
Stock chart
Analyses on Teva (10)
- May 3, 2026
- April 30, 2026April 30, 2026
- Follow-up
Teva in Q1: the legal provision fell, the payment schedule remains heavy
Teva’s legal tail is still moving from vague risk into a visible payment schedule, but the provision decline to $4.680 billion is not enough to change the cash test. Opioid and DOJ PAP payments for 2026 through 2030 total $2.242 billion before COPAXONE Europe and follow-on claim…

- Follow-up
Teva in Q1: who captures the value if the externally funded pipeline works
Teva is lowering its current R&D burden through partner-funded pipeline structures, but today's relief comes with future partner rights through milestones, royalties, success payments and profit-sharing.

Teva in Q1: innovative medicines are carrying growth, but cash quality still needs proof
Teva opened 2026 with further evidence that AUSTEDO, AJOVY and UZEDY are changing the company’s economics, but negative operating cash flow and reliance on receivables securitization leave the cash-quality test open.

Teva buys Emalex and weighs a buyback, but the same cash flow has too many jobs
Teva has enough operating improvement to consider external M&A and a possible buyback, but Q1 shows that the same cash still has to fund Emalex, debt, legal payments, and development.

- April 24, 2026


